Clinical Context
Peer-reviewed veterinary literature continues to shape everyday decision-making for canine patients, especially when new evidence clarifies diagnosis, treatment selection, monitoring, or clinical outcomes.
What the Study Evaluated
A study published in Frontiers in veterinary science in 2026 evaluated overall survival with beraprost in dogs with IRIS stage 2 chronic kidney disease..
Key Findings
Chronic kidney disease (CKD) in dogs is a progressive condition with a poor prognosis and a lack of effective pharmacological interventions to extend survival. Beraprost, an oral prostacyclin analog approved for feline CKD, was off-label prescribed and evaluated for its effect on survival in dogs with naturally occurring IRIS stage 2 CKD. This prospective clinical study included a treatment group ( n = 16) receiving oral beraprost (12.5 μg/kg twice daily), and a well-matched historical control group ( n = 17) from the same institution. The primary outcome, overall survival, was analyzed using the Kaplan-Meier method and a multivariable Cox...
Why It Matters for Veterinary Professionals
For veterinary professionals, the practical value of this work lies in how the findings may support more structured clinical assessment, clearer monitoring, and more informed decisions for canine patients.
Practical Interpretation
The results should be interpreted in the context of the study design, population, inclusion criteria, and clinical setting. Application in practice should consider patient-specific risk factors, available diagnostics, local standards of care, and clinician judgment.
Clinical Takeaway
Overall, the study adds useful evidence for clinicians seeking to align daily practice with current veterinary research while maintaining a balanced, case-by-case approach.
Read the full article here.
List
Add
Please enter a comment